The present invention relates to an apparatus for bypassing a blocked blood vessel segment, and, more particularly, to a conduit or stent positioned between the coronary artery or other blocked vessel and a chamber of the heart, such as the left ventricle of the heart, to bypass a blocked segment of the coronary artery or other blood vessel.
Coronary artery disease is a major problem in the U.S. and throughout the world. Coronary arteries as well as other blood vessels frequently become clogged with plaque, which at the very least impairs the efficiency of the heart's pumping action, and can lead to heart attack and death. In some cases, these arteries can be unblocked through non-invasive techniques such as balloon angioplasty. In more difficult cases, a bypass of the blocked vessel is necessary.
In a bypass operation, one or more venous segments are inserted between the aorta and the coronary artery. The inserted venous segments or transplants act as a bypass of the blocked portion of the coronary artery and thus provide for a free or unobstructed flow of blood to the heart. More than 500,000 bypass procedures are performed in the U.S. every year.
Such coronary artery bypass surgery, however, is a very intrusive procedure that is expensive, time-consuming and traumatic to the patient. The operation requires an incision through the patient's sternum (sternotomy), and that the patient be placed on a bypass pump so that the heart can be operated on while not beating. A vein graft is harvested from the patient's leg, another highly invasive procedure, and a delicate surgical procedure is required to piece the bypass graft to the coronary artery (anastomosis). Hospital stays subsequent to the surgery and convalescence are prolonged.
As mentioned above, another conventional treatment is percutaneous transluminal coronary angioplasty (PTCA) or other types of angioplasty. However, such vascular treatments are not always indicated due to the type or location of the blockage, or due to the risk of emboli.
Thus, there is a need for an improved bypass system which is less traumatic to the patient.
The preferred embodiments of the present invention address the need in the previous technology by providing a bypass system that avoids the sternotomy and other intrusive procedures normally associated with coronary bypass surgery. These embodiments also free the surgeon from the multiple anastomoses necessary in the current process.
The preferred device provides a shunt for diverting blood directly from a chamber in the heart, such as the left ventricle, to the coronary artery, distal to the blockage, therefore bypassing the blocked portion of the vessel. The shunt comprises a stent or conduit adapted to be positioned in the heart wall or myocardium between a chamber in the heart such as the left ventricle and the coronary artery that allows for the direct passage of blood therethrough. As used herein, the terms “stent” and “conduit” are interchangeable, and refer to a device that allows for the passage of blood therethrough. The terms “myocardium” and “heart wall” are also used interchangeably. In addition, although the left ventricle is referred to throughout the description, it should be understood that the conduit described herein can be used to provide a passageway for the flow of blood from any heart chamber, not only the left ventricle.
The stent device is delivered either externally or internally through the coronary artery to a position distal to the blockage. At that position, the coronary artery, the myocardium and the wall of the left ventricle are pierced to provide a channel completely through from the coronary artery to the left ventricle of the heart. The stent is then positioned in the channel to provide a permanent passage for blood to flow between the left ventricle of the heart and the coronary artery, distal to the blockage. The stent is sized so that one open end is positioned within the coronary artery, while the other open end is positioned in the left ventricle. The hollow lumen of the stent provides a passage for the flow of blood.
The stent can be self-expandable or expanded by means of a balloon or similar device, and can be provided with various means to anchor it in position, such as expandable legs, hooks, barbs, flanges, collars, loops, wires, flares, suture holes and the like. The anchoring means can be adapted to anchor the conduit in the heart wall, or alternatively, in the coronary artery. The stent can be formed from a plurality of rings, which can be connected to provide stability. The stent can include a valve in its interior, and can also be used to deliver drugs or other pharmaceutical compounds directly into the myocardium and the coronary circulation.
Briefly stated, the methods and apparatus described and illustrated herein generally relate to direct coronary revascularization, wherein a conduit or opening is provided from the left ventricle to the coronary artery, oftentimes the left anterior descending (LAD), to provide blood flow directly therethrough. The conduit of the preferred embodiments has a distal top which is more preferably a ball top, wire top, flare top or flip-down top. These top configurations anchor the shunt at one end in the coronary artery.
As is well known, the coronary artery branches off the aorta and is positioned along the external surface of the heart wall. The anatomy of the human heart is illustrated in FIG. 1A. Oxygenated blood flows from the heart PH to the aorta AO, on to the rest of the body, some of the blood flowing into the coronary artery CA. In some individuals, plaque builds up within the coronary artery CA, blocking the free flow of blood and causing complications ranging from mild angina to heart attack and death.
In order to restore the flow of oxygenated blood through the coronary artery, one embodiment of the present invention provides for the shunting of blood directly from the heart to a site in the coronary artery that is distal to the blockage. A channel is formed through the wall of the coronary artery and the myocardium and into the left ventricle of the heart that lies beneath the coronary artery. A stent or conduit is positioned in the passage to keep it open, and allow for the flow of oxygenated blood directly from the heart into the coronary artery. Again, it should be understood that while the insertion of the conduit in the myocardium between the left ventricle and the coronary artery is described in detail below, this is merely exemplary and use of the conduit between other chambers of the heart and the coronary artery, and between blood vessels is also contemplated.
The principles of the present invention are not limited to left ventricular conduits, and include conduits for communicating bodily fluids from any space within a patient to another space within a patient, including any mammal. Furthermore, such fluid communication through the conduits is not limited to any particular direction of flow and can be antegrade or retrograde with respect to the normal flow of fluid. Moreover, the conduits may communicate between a bodily space and a vessel or from one vessel to another vessel (such as an artery to a vein or vice versa). Moreover, the conduits can reside in a single bodily space so as to communicate fluids from one portion of the space to another. For example, the conduits can be used to achieve a bypass within a single vessel, such as communicating blood from a proximal portion of an occluded coronary artery to a more distal portion of that same coronary artery.
In addition, the conduits and related methods can preferably traverse various intermediate destinations and are not limited to any particular flow sequence. For example, in one preferred embodiment of the present invention, the conduit communicates from the left ventricle, through the myocardium, into the pericardial space, and then into the coronary artery. However, other preferred embodiments are disclosed, including direct transmyocardial communication from a left ventricle, through the myocardium and into the coronary artery. Thus, as emphasized above, the term “transmyocardial” should not be narrowly construed in connection with the preferred fluid communication conduits, and other non-myocardial and even noncardiac fluid communication are preferred as well. With respect to the walls of the heart (and more specifically the term “heart wall”), the preferred conduits and related methods are capable of fluid communication through all such walls including, without limitation, the pericardium, epicardium, myocardium, endocardium, septum, etc.
The bypass which is achieved with certain preferred embodiments and related methods is not limited to a complete bypass of bodily fluid flow, but can also include a partial bypass which advantageously supplements the normal bodily blood flow. Moreover, the occlusions which are bypassed may be of a partial or complete nature, and therefore the terminology “bypass” or “occlusion” should not be construed to be limited to a complete bypass or a complete occlusion but can include partial bypass and partial occlusion as described.
The preferred conduits and related methods disclosed herein can also provide complete passages or partial passages through bodily tissues. In this regard, the conduits can comprise stents, shunts, or the like, and therefore provide a passageway or opening for bodily fluid such as blood. Moreover, the conduits are not necessarily stented or lined with a device but can comprise mere tunnels or openings formed in the tissues of the patient.
The conduits of the present invention preferably comprise both integral or one-piece conduits as well as plural sections joined together to form a continuous conduit. The present conduits can be deployed in a variety of methods consistent with sound medical practice including vascular or surgical deliveries, including minimally invasive techniques. For example, various preferred embodiments of delivery rods and associated methods may be used. In one embodiment, the delivery rod is solid and trocar-like. It may be rigid or semi-rigid and capable of penetrating the tissues of the patient and thereby form the conduit, in whole or in part, for purposes of fluid communication. In other preferred embodiments, the delivery rods may be hollow so as to form the conduits themselves (e.g., the conduits are preferably self-implanting or self-inserting) or have a conduit mounted thereon (e.g., the delivery rod is preferably withdrawn leaving the conduit installed). Thus, the preferred conduit device and method for installation is preferably determined by appropriate patient indications in accordance with sound medical practices.
In some individuals, aortic insufficiency or peripheral venous insufficiency occurs. Aortic insufficiency is the leakage of blood through the aortic valve, resulting in a backflow of blood into the left ventricle. The heart compensates for the backflow of blood by pumping harder, resulting in hypertrophy (thickening of the heart muscle) and dilation of the left ventricle wall. Left untreated, heart failure can result. In venous insufficiency, the heart valves are unable to prevent the backflow of blood. This too can result in heart failure. Accordingly, one embodiment of the invention provides for the use of a conduit placed within the heart wall to improve the flow of oxygenated blood through the body.
Balloon Expanded Stent
A first embodiment of the present invention is illustrated in FIG. 1B. This embodiment is a balloon-expanded stent 10. The stent 10 is introduced as described below, using a high-pressure balloon catheter 12 to deploy the stent 10 once it is properly positioned in the myocardium MYO (FIG. 2). When the stent 10 is positioned inside the myocardial wall MYO, the balloon 14 is inflated to expand the stent 10 and open the conduit from the left ventricle LV into the coronary artery CA. The stent 10 can include attachment mechanisms not limited to hooks, barbs, flanges, large collars, suture holes and/or other means to ensure a seal is created between the coronary artery CA and the wall of the myocardium MYO and to prevent the threat of stent 10 migration. When the attachment of the stent 10 is completed, the remaining catheter assembly 12 is removed, leaving the stent 10 in place. Upon deflating the balloon 14, the stent 10 will remain open. Because of the shape of this stent 10, a dumbbell shaped balloon 14 is preferably used to ensure proper expansion, as described below.
Self Expanding Stent
The second embodiment of the stent or conduit incorporates a self-expanding stent 20, illustrated in
The self-expanding stent 20 mounted on the distal end of the stent introducer catheter 22 is illustrated in FIG. 5.
For the stent designs described above, additional anchoring methods may be desired to maintain the stent's proper position and/or create a leak-free seal in the coronary artery. Suitable attachment mechanisms include a set of barbs located on the stent body or flares and a collar on the coronary side to help seal and prevent blood from exiting the gap between the vessel and outer heart wall. The stent can also be anchored in place by applying sutures. The stent can include holes at either end to facilitate the placement of these anchoring sutures. A suture gun can be used to apply multiple sutures at the same time. In addition, the stents can be lined, if desired, with materials such as polymers, for example polytetrafluoroethylene (PTFE), silicone or GORTEX to provide for the ease of blood flow therethrough.
Stent with Attachment Flanges
A third embodiment of the stent design, illustrated in
Biodegradable Stent
If desired, the stent or conduit of the present invention can be formed of biodegradable or bioabsorbable materials and/or used to deliver drugs directly into the myocardium and the coronary circulation. Such a stent 52 is illustrated in FIG. 13. The biodegradable stent 52 can extend only partially through the myocardium MYO as illustrated in
Bulkhead Stent
If desired, the separate units or rings of the stent 50 can be connected via a wire, suture thread, or similar means. The wire is threaded through the holes 51 located in each ring. Connecting the rings of the stent 50 in this manner serves to make the stent 50 more stable and to prevent the migration of the individual units. If desired, a valve (not shown) can be incorporated into the stent 50 to help prevent the backflow of blood into the left ventricle LV.
Turning now to
Screw Stent
Stent with Retention Members
Distal Top Shunts
In another embodiment, as illustrated in
Wire loops 318 are preferably attached to the distal end 314 to form the distal top. The wire loops preferably form a generally ball-shaped configuration, with the diameter of the ball corresponding approximately with the diameter of the artery. When implanted, the wire loops 318 are preferably located in the coronary artery CA to hold the shunt therein. The wire loops 318 preferably expand beyond the diameter of the tubular body. Therefore, these loops are preferably collapsible such that they can be inserted into a delivery tube, as described below.
Although
Hinged Conduit
Additional embodiments include conduits which are engaged and aligned with the left ventricle and the coronary artery in the patient's heart.
Bell-Shape Conduit
Conduit Having Annular Grooves
Single Loop Conduit
Conduit with Rotating Sheath and Deployable Flanges
It should be appreciated that the stents and conduits described above, and particularly the bulkhead stent, are useful in other applications in addition to stenting the myocardium. For example, these stents may also serve as other types of coronary stents, arterial or venous stents, as well as billiary and esophageal stents.
The present vascular shunt provides significant improvements in the present treatment of blockages in the coronary artery. Although the invention has been described in its preferred embodiments in connection with the particular figures, it is not intended that this description should be limited in any way.
This is a continuation of U.S. patent application Ser. No. 09/787,801, now abandoned that entered the U.S. National Stage on Mar. 23, 2001, based on international Application No. PCT/US99/20714, filed Sep. 10, 1999, which is a con. of U.S. application Ser. No. 09/369,048, filed Aug. 4, 1999 and U.S. Provisional Application Nos. 60/099,767, filed on Sep. 10, 1998; 60/104,397, filed on Oct. 15, 1998; 60/147,202, filed on Aug. 4, 1999; and 60/147,218, filed on Aug. 4, 1999, all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2127903 | Bowen | Aug 1938 | A |
3620218 | Schmitt et al. | Nov 1971 | A |
4267202 | Nakayama et al. | May 1981 | A |
4508606 | Andrade et al. | Apr 1985 | A |
4786556 | Hu et al. | Nov 1988 | A |
4953553 | Tremulis | Sep 1990 | A |
5034265 | Hoffman et al. | Jul 1991 | A |
5132108 | Narayanan et al. | Jul 1992 | A |
5169675 | Bartoszek-Loza et al. | Dec 1992 | A |
5190058 | Jones et al. | Mar 1993 | A |
5226889 | Sheiban | Jul 1993 | A |
5229163 | Fox | Jul 1993 | A |
5229172 | Cahalan et al. | Jul 1993 | A |
5308704 | Suzuki et al. | May 1994 | A |
5336518 | Narayanan et al. | Aug 1994 | A |
5389096 | Aita et al. | Feb 1995 | A |
5455040 | Marchant | Oct 1995 | A |
5456694 | Marin et al. | Oct 1995 | A |
5554119 | Harrison et al. | Sep 1996 | A |
5597456 | Maruyama et al. | Jan 1997 | A |
5643278 | Wijay | Jul 1997 | A |
5643580 | Subramaniam | Jul 1997 | A |
5676670 | Kim | Oct 1997 | A |
5700742 | Payne | Dec 1997 | A |
5723219 | Kolluri et al. | Mar 1998 | A |
5733267 | Del Toro | Mar 1998 | A |
5782908 | Cahalan et al. | Jul 1998 | A |
5797920 | Kim | Aug 1998 | A |
5807384 | Mueller | Sep 1998 | A |
5810871 | Tuckey et al. | Sep 1998 | A |
5876373 | Giba et al. | Mar 1999 | A |
5885259 | Berg | Mar 1999 | A |
5922022 | Nash et al. | Jul 1999 | A |
5925012 | Murphy-Chutorian et al. | Jul 1999 | A |
5931848 | Saadat | Aug 1999 | A |
5938632 | Ellis | Aug 1999 | A |
5962138 | Kolluri et al. | Oct 1999 | A |
5968064 | Selmon et al. | Oct 1999 | A |
5976153 | Fischell et al. | Nov 1999 | A |
5976155 | Foreman et al. | Nov 1999 | A |
5979455 | Maginot | Nov 1999 | A |
5980530 | Willard et al. | Nov 1999 | A |
5980533 | Holman | Nov 1999 | A |
5989263 | Shmulewitz | Nov 1999 | A |
5999678 | Murphy-Chutorian et al. | Dec 1999 | A |
6007543 | Ellis et al. | Dec 1999 | A |
6010449 | Selmon et al. | Jan 2000 | A |
6013855 | McPherson et al. | Jan 2000 | A |
6026814 | LaFontaine et al. | Feb 2000 | A |
6035856 | LaFontaine et al. | Mar 2000 | A |
6036677 | Javier, Jr. et al. | Mar 2000 | A |
6036697 | DiCaprio | Mar 2000 | A |
6039721 | Johnson et al. | Mar 2000 | A |
6042581 | Ryan et al. | Mar 2000 | A |
6056743 | Ellis et al. | May 2000 | A |
6080170 | Nash et al. | Jun 2000 | A |
6092526 | LaFontaine et al. | Jul 2000 | A |
6093177 | Javier, Jr. et al. | Jul 2000 | A |
6093185 | Ellis et al. | Jul 2000 | A |
6120520 | Saadat et al. | Sep 2000 | A |
6124523 | Banas et al. | Sep 2000 | A |
6126654 | Giba et al. | Oct 2000 | A |
6132451 | Payne et al. | Oct 2000 | A |
6155264 | Ressemann et al. | Dec 2000 | A |
6156031 | Aita et al. | Dec 2000 | A |
6157852 | Selmon et al. | Dec 2000 | A |
6159531 | Dang et al. | Dec 2000 | A |
6165185 | Shennib et al. | Dec 2000 | A |
6165188 | Saadat et al. | Dec 2000 | A |
6171251 | Mueller et al. | Jan 2001 | B1 |
6193734 | Bolduc et al. | Feb 2001 | B1 |
6197324 | Crittenden | Mar 2001 | B1 |
6200311 | Danek et al. | Mar 2001 | B1 |
6213126 | LaFontaine et al. | Apr 2001 | B1 |
6217527 | Selmon et al. | Apr 2001 | B1 |
6217549 | Selmon et al. | Apr 2001 | B1 |
6217575 | DeVore et al. | Apr 2001 | B1 |
6221049 | Selmon et al. | Apr 2001 | B1 |
6224584 | March et al. | May 2001 | B1 |
6231546 | Milo et al. | May 2001 | B1 |
6231551 | Barbut | May 2001 | B1 |
6235000 | Milo et al. | May 2001 | B1 |
6241667 | Vetter et al. | Jun 2001 | B1 |
6251079 | Gambale et al. | Jun 2001 | B1 |
6251104 | Kesten et al. | Jun 2001 | B1 |
6251116 | Shennib et al. | Jun 2001 | B1 |
6251418 | Ahern et al. | Jun 2001 | B1 |
6253769 | LaFontaine et al. | Jul 2001 | B1 |
6258052 | Milo | Jul 2001 | B1 |
6277449 | Kolluri et al. | Aug 2001 | B1 |
6285903 | Rosenthal et al. | Sep 2001 | B1 |
6290709 | Ellis et al. | Sep 2001 | B1 |
6290728 | Phelps et al. | Sep 2001 | B1 |
6299787 | Li et al. | Oct 2001 | B1 |
6322548 | Payne et al. | Nov 2001 | B1 |
6363939 | Wilk | Apr 2002 | B1 |
6387119 | Wolf et al. | May 2002 | B2 |
6390098 | LaFontaine et al. | May 2002 | B1 |
6402740 | Ellis et al. | Jun 2002 | B1 |
6409751 | Hall et al. | Jun 2002 | B1 |
6416490 | Ellis et al. | Jul 2002 | B1 |
6432119 | Saadat | Aug 2002 | B1 |
6440166 | Kolluri | Aug 2002 | B1 |
6443158 | LaFontaine et al. | Sep 2002 | B1 |
6458092 | Gambale et al. | Oct 2002 | B1 |
6458140 | Akin et al. | Oct 2002 | B2 |
6458323 | Boekstegers | Oct 2002 | B1 |
6461665 | Scholander | Oct 2002 | B1 |
6475226 | Belef et al. | Nov 2002 | B1 |
6475244 | Herweck et al. | Nov 2002 | B2 |
6482220 | Mueller | Nov 2002 | B1 |
6491689 | Ellis et al. | Dec 2002 | B1 |
6491707 | Makower et al. | Dec 2002 | B2 |
6506408 | Palasis | Jan 2003 | B1 |
6508825 | Selmon et al. | Jan 2003 | B1 |
6511458 | Milo et al. | Jan 2003 | B2 |
6514217 | Selmon et al. | Feb 2003 | B1 |
6514271 | Evans et al. | Feb 2003 | B2 |
6517527 | Gambale et al. | Feb 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6524323 | Nash et al. | Feb 2003 | B1 |
6544230 | Flaherty | Apr 2003 | B1 |
6559132 | Holmer | May 2003 | B1 |
6561998 | Roth et al. | May 2003 | B1 |
6565528 | Mueller | May 2003 | B1 |
6565594 | Herweck et al. | May 2003 | B1 |
6569145 | Shmulewitz et al. | May 2003 | B1 |
6569147 | Evans et al. | May 2003 | B1 |
6573311 | Martakos et al. | Jun 2003 | B1 |
6575168 | LaFontaine et al. | Jun 2003 | B2 |
6579311 | Makower | Jun 2003 | B1 |
6582444 | Wilk | Jun 2003 | B2 |
6599304 | Selmon et al. | Jul 2003 | B1 |
6605113 | Wilk | Aug 2003 | B2 |
6610100 | Phelps et al. | Aug 2003 | B2 |
6613081 | Kim et al. | Sep 2003 | B2 |
6616675 | Evard et al. | Sep 2003 | B1 |
6616876 | Labrecque et al. | Sep 2003 | B1 |
6638237 | Guiles et al. | Oct 2003 | B1 |
6638247 | Selmon et al. | Oct 2003 | B1 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641610 | Wolf et al. | Nov 2003 | B2 |
6651670 | Rapacki et al. | Nov 2003 | B2 |
6652540 | Cole et al. | Nov 2003 | B1 |
6652546 | Nash et al. | Nov 2003 | B1 |
6655386 | Makower et al. | Dec 2003 | B1 |
6660003 | DeVore et al. | Dec 2003 | B1 |
6660024 | Flaherty et al. | Dec 2003 | B1 |
6669709 | Cohn et al. | Dec 2003 | B1 |
6685648 | Flaherty et al. | Feb 2004 | B2 |
6694983 | Wolf et al. | Feb 2004 | B2 |
20010000041 | Selmon et al. | Mar 2001 | A1 |
20010003985 | Lafontaine et al. | Jun 2001 | A1 |
20010008969 | Evans et al. | Jul 2001 | A1 |
20010018596 | Selmon et al. | Aug 2001 | A1 |
20010020172 | Selmon et al. | Sep 2001 | A1 |
20010029385 | Shennib et al. | Oct 2001 | A1 |
20010034547 | Hall et al. | Oct 2001 | A1 |
20010037149 | Wilk | Nov 2001 | A1 |
20010039445 | Hall et al. | Nov 2001 | A1 |
20010044631 | Akin et al. | Nov 2001 | A1 |
20010049523 | DeVore et al. | Dec 2001 | A1 |
20010053932 | Phleps et al. | Dec 2001 | A1 |
20020004662 | Wilk | Jan 2002 | A1 |
20020007138 | Wilk et al. | Jan 2002 | A1 |
20020058897 | Renati | May 2002 | A1 |
20020077654 | Javier, Jr. et al. | Jun 2002 | A1 |
20020092535 | Wilk | Jul 2002 | A1 |
20020092536 | LaFontaine et al. | Jul 2002 | A1 |
20020095206 | Addonizio et al. | Jul 2002 | A1 |
20020100484 | Hall et al. | Aug 2002 | A1 |
20020138087 | Shennib et al. | Sep 2002 | A1 |
20020143285 | Eno et al. | Oct 2002 | A1 |
20020143289 | Ellis et al. | Oct 2002 | A1 |
20020161383 | Akin et al. | Oct 2002 | A1 |
20020165479 | Wilk | Nov 2002 | A1 |
20020165606 | Wolf et al. | Nov 2002 | A1 |
20020179098 | Makower et al. | Dec 2002 | A1 |
20020183716 | Herweck et al. | Dec 2002 | A1 |
20020193782 | Ellis et al. | Dec 2002 | A1 |
20030018379 | Knudson et al. | Jan 2003 | A1 |
20030044315 | Boekstegers | Mar 2003 | A1 |
20030045828 | Wilk | Mar 2003 | A1 |
20030055371 | Wolf et al. | Mar 2003 | A1 |
20030073973 | Evans et al. | Apr 2003 | A1 |
20030078561 | Gambale et al. | Apr 2003 | A1 |
20030100920 | Akin et al. | May 2003 | A1 |
20030105514 | Phelps et al. | Jun 2003 | A1 |
20030120195 | Milo et al. | Jun 2003 | A1 |
20030149474 | Becker | Aug 2003 | A1 |
20030158573 | Gittings et al. | Aug 2003 | A1 |
20030163198 | Morra et al. | Aug 2003 | A1 |
20030181938 | Roth et al. | Sep 2003 | A1 |
20030191449 | Nash et al. | Oct 2003 | A1 |
20030195457 | LaFontaine et al. | Oct 2003 | A1 |
20030195458 | Phelps et al. | Oct 2003 | A1 |
20030204160 | Kamm et al. | Oct 2003 | A1 |
20030212413 | Wilk | Nov 2003 | A1 |
20030216679 | Wolf et al. | Nov 2003 | A1 |
20030229366 | Makower | Dec 2003 | A1 |
20030236542 | Makower | Dec 2003 | A1 |
20040006298 | Wilk | Jan 2004 | A1 |
20040015225 | Kim et al. | Jan 2004 | A1 |
20040019348 | Stevens et al. | Jan 2004 | A1 |
20040044392 | Van Oepen | Mar 2004 | A1 |
Number | Date | Country |
---|---|---|
757647 | Aug 1999 | AU |
0 104 608 | Apr 1984 | EP |
0 104 608 | Apr 1984 | EP |
0 124 200 | Nov 1984 | EP |
0 351 314 | Jan 1990 | EP |
0 426 486 | May 1991 | EP |
0 519 087 | Dec 1992 | EP |
0 623 354 | Nov 1994 | EP |
0 627 226 | Dec 1994 | EP |
0 714 270 | Jun 1996 | EP |
0 714 487 | Jun 1996 | EP |
0 758 953 | Feb 1997 | EP |
0 775 472 | May 1997 | EP |
0 815 798 | Jul 1997 | EP |
0 829 239 | Aug 1997 | EP |
0 792 624 | Sep 1997 | EP |
0 797 957 | Oct 1997 | EP |
0 797 958 | Oct 1997 | EP |
0 799 604 | Oct 1997 | EP |
0 801 928 | Oct 1997 | EP |
0 836 834 | Oct 1997 | EP |
0 809 999 | Dec 1997 | EP |
0 876 796 | May 1998 | EP |
0 853 921 | Jul 1998 | EP |
0 858 779 | Aug 1998 | EP |
0 873 732 | Oct 1998 | EP |
0 888 750 | Jan 1999 | EP |
0 895 752 | Feb 1999 | EP |
0 934 728 | Aug 1999 | EP |
0 941 740 | Sep 1999 | EP |
1 088 564 | Apr 2001 | EP |
1 181 943 | Feb 2002 | EP |
0 959 815 | Dec 2002 | EP |
1 112 098 | Feb 2003 | EP |
2 257 147 | Jan 1993 | GB |
WO 9221387 | Dec 1992 | WO |
WO 9505132 | Feb 1995 | WO |
WO 9529647 | Nov 1995 | WO |
WO 9628115 | Sep 1996 | WO |
WO 9632972 | Oct 1996 | WO |
WO 9635469 | Nov 1996 | WO |
WO 9639962 | Dec 1996 | WO |
WO 9639964 | Dec 1996 | WO |
WO 9639965 | Dec 1996 | WO |
WO 9722631 | Jun 1997 | WO |
WO 9749434 | Dec 1997 | WO |
WO 9800090 | Jan 1998 | WO |
WO 9803118 | Jan 1998 | WO |
WO 9808456 | Mar 1998 | WO |
WO 9810116 | Mar 1998 | WO |
WO 9810806 | Mar 1998 | WO |
WO 9812990 | Apr 1998 | WO |
WO 9824373 | Jun 1998 | WO |
WO 9825533 | Jun 1998 | WO |
WO 9825549 | Jun 1998 | WO |
WO 9826731 | Jun 1998 | WO |
WO 9838916 | Sep 1998 | WO |
WO 9838925 | Sep 1998 | WO |
WO 9838939 | Sep 1998 | WO |
WO 9838941 | Sep 1998 | WO |
WO 9839038 | Sep 1998 | WO |
WO 9846115 | Oct 1998 | WO |
WO 9857590 | Dec 1998 | WO |
WO 9857592 | Dec 1998 | WO |
WO 9907296 | Feb 1999 | WO |
WO 9915220 | Apr 1999 | WO |
WO 9917671 | Apr 1999 | WO |
WO 9922658 | May 1999 | WO |
WO 9922670 | May 1999 | WO |
WO 9927985 | Jun 1999 | WO |
WO 9935977 | Jul 1999 | WO |
WO 9935979 | Jul 1999 | WO |
WO 9935980 | Jul 1999 | WO |
WO 9938455 | Aug 1999 | WO |
WO 9940853 | Aug 1999 | WO |
WO 9940963 | Aug 1999 | WO |
WO 9944524 | Sep 1999 | WO |
WO 9947077 | Sep 1999 | WO |
WO 9948549 | Sep 1999 | WO |
WO 0012029 | Mar 2000 | WO |
WO 0013719 | Mar 2000 | WO |
WO 0013722 | Mar 2000 | WO |
WO 0018323 | Apr 2000 | WO |
WO 0018328 | Apr 2000 | WO |
WO 0018462 | Apr 2000 | WO |
WO 0023124 | Apr 2000 | WO |
WO 0038590 | Jul 2000 | WO |
WO 0043051 | Jul 2000 | WO |
WO 0045886 | Aug 2000 | WO |
WO 0048530 | Aug 2000 | WO |
WO 0049952 | Aug 2000 | WO |
WO 0049954 | Aug 2000 | WO |
WO 0049956 | Aug 2000 | WO |
WO 0054660 | Sep 2000 | WO |
WO 0054661 | Sep 2000 | WO |
WO 0056224 | Sep 2000 | WO |
WO 0056225 | Sep 2000 | WO |
WO 0069345 | Nov 2000 | WO |
WO 0069504 | Nov 2000 | WO |
WO 0106953 | Feb 2001 | WO |
WO 0108566 | Feb 2001 | WO |
WO 0115633 | Mar 2001 | WO |
Number | Date | Country | |
---|---|---|---|
20020058897 A1 | May 2002 | US |
Number | Date | Country | |
---|---|---|---|
60147218 | Aug 1999 | US | |
60147202 | Aug 1999 | US | |
60104397 | Oct 1998 | US | |
60099767 | Sep 1998 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09787801 | US | |
Child | 09956099 | US | |
Parent | 09369048 | Aug 1999 | US |
Child | 09787801 | US |